All Helmholtz Munich articles
-
NewsTherapeutic vaccine for chronic hepatitis B enters first clinical trial in patients
TherVacB, a novel therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. A successful phase 1a trial in healthy volunteers saw the vaccine demonstrate a favorable safety profile and trigger the desired immune responses.
-
NewsClinical trials reveal promising alternatives to high-toxicity tuberculosis drug
Research shows two novel antibiotics could spare patients from severe side effects. The drugs sutezolid and delpazolid have demonstrated strong antimicrobial activity and a notably better safety profile compared to linezolid.
-
NewsNew microscope harnesses bioluminescence to bring glowing cells into focus
Researchers have developed a new microscope that significantly improves how bioluminescent signals in living cells can be observed. The system, known as QIScope, is built around a highly sensitive camera technology capable of detecting extremely low levels of light.
-
NewsAncient viral DNA shapes early embryo development
Over half of our genomes consists of remnants of ancient viral DNA which are widespread across the tree of life. Once dismissed as the ’dark side’ of the genome, researchers have now revealed the role of transposable elements in early embryo development.
-
NewsStart-up EBViously announces its launch
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV).
-
NewsInnovative antiviral defense with new CRISPR tool
Scientists outline how they have overcome a significant obstacle that has hampered the effectiveness of Cas13d: its restriction to the nucleus of mammalian cells.
-
NewsAchilles heel is uncovered in Helicobacter pylori
Researchers have discovered a weakness in the bacterium Helicobacter pylori, which could be exploited to develop new drugs.